- £161.26bn
- £179.84bn
- $54.07bn
- 86
- 16
- 74
- 64
REG - AstraZeneca PLC - Update on CAPItello-280 Phase III trial
AnnouncementREG - AstraZeneca PLC - 1st Quarter Results
AnnouncementREG - AstraZeneca PLC - Enhertu combination improved PFS in 1L HER2+ mBC
AnnouncementRCS - OMP - OMP Positioned Highest for Ability to Execute
AnnouncementREG - AstraZeneca PLC - Result of AGM
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for AEGEAN
AnnouncementREG - AstraZeneca PLC - Enhertu approved in EU in post-ET breast cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in the US for bladder cancer
AnnouncementREG - AstraZeneca PLC - Calquence recommended for EU approval in 1L MCL
AnnouncementREG - AstraZeneca PLC - AZN invests $2.5bn in Beijing R&D & manufacturing
AnnouncementREG - AstraZeneca PLC - AstraZeneca to acquire EsoBiotec
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for limited-stage SCLC
AnnouncementREG - AstraZeneca PLC - Eneboparatide Phase III trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementREG - AstraZeneca PLC - Imfinzi improved EFS in early-stage gastric cancer
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
Announcement